Background Metabolic-associated steatotic liver disease (MASLD) is a prevalent chronic liver disease affecting approximately ...

The BMP8A Fibrosis Score (BFS) offers improved accuracy over existing noninvasive scoring systems for identifying advanced liver fibrosis in MASH patients. BFS eliminates grey-zone results, providing ...

Liver fibrosis may be diagnosed and staged — no fibrosis (stage F0), mild fibrosis (F1), significant fibrosis (F2), advanced fibrosis (F3), and cirrhosis (F4) — with the use of clinical parameters and ...

New research shows an AI-driven liquid biopsy analyzing genome-wide cfDNA fragment patterns can detect early liver fibrosis & cirrhosis and may signal broader chronic disease burden.

A new blood test can help the early identification of liver scarring in liver disease. Learn more about this study.

Elexacaftor-tezacaftor-ivacaftor combination therapy shows no clinically meaningful improvement in bone health or calcium metabolism in patients with cystic fibrosis, a Danish study shows.